Healthcare / BiotechnologyASX
$0.05
-0.00 (-5.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-35.4M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$74M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.5%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-42.7M · FCF $-35.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $170369.00 | — |
| Net Income | $-42.7M | $-42.7M | $-39.9M | $-32.2M | $-29.9M |
| EBITDA | $-42.7M | $-42.7M | $-39.9M | $-32.1M | $-29.9M |
| EPS | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 |
| Operating Margin | — | — | — | -19861.2% | — |
| Net Margin | — | — | — | -18906.5% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 |
| Current Ratio | 2.97 | 2.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-35.8M | $-35.8M | $-35.4M | $-30.3M | $-17.7M |
| Returns | |||||
| ROE | -22.5% | -22.5% | -29.2% | -34.2% | -40.8% |
| Valuation | |||||
| P/B | 0.32 | 0.32 | 2.03 | 2.89 | 4.22 |
| Growth & Yield | |||||
| EPS Growth | 20.4% | 20.4% | -17.9% | 22.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-81.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.04
Residual
-81.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.